Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆
Titel:
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆
Auteur:
Wu, X.H. Zhu, J.Q. Yin, R.T. Yang, J.X. Liu, J.H. Wang, J. Wu, L.Y. Liu, Z.L. Gao, Y.N. Wang, D.B. Lou, G. Yang, H.Y. Zhou, Q. Kong, B.H. Huang, Y. Chen, L.P. Li, G.L. An, R.F. Wang, K. Zhang, Y. Yan, X.J. Lu, X. Lu, W.G. Hao, M. Wang, L. Cui, H. Chen, Q.H. Abulizi, G. Huang, X.H. Tian, X.F. Wen, H. Zhang, C. Hou, J.M. Mirza, M.R.